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Clinical manifestations of atherothrombotic disease, such as acute coronary syndromes, cerebrovascular events, and peripheral arterial
disease, are major causes of mortality and morbidity worldwide. Platelet activation and aggregation are ultimately responsible for the pro-
gression and clinical presentations of atherothrombotic disease. The current standard of care, dual oral antiplatelet therapy with aspirin and
the P2Y12 adenosine diphosphate (ADP) receptor inhibitor clopidogrel, has been shown to improve outcomes in patients with atherothrom-
botic disease. However, aspirin and P2Y12 inhibitors target the thromboxane A2 and the ADP P2Y12 platelet activation pathways and mini-
mally affect other pathways, while agonists such as thrombin, considered to be the most potent platelet activator, continue to stimulate
platelet activation and thrombosis. This may help explain why patients continue to experience recurrent ischaemic events despite receiving
such therapy. Furthermore, aspirin and P2Y12 receptor antagonists are associated with bleeding risk, as the pathways they inhibit are critical
for haemostasis. The challenge remains to develop therapies that more effectively inhibit platelet activation without increasing bleeding com-
plications. The inhibition of the protease-activated receptor-1 (PAR-1) for thrombin has been shown to inhibit thrombin-mediated platelet
activation without increasing bleeding in pre-clinical models and small-scale clinical trials. PAR-1 inhibition in fact does not interfere with
thrombin-dependent ﬁbrin generation and coagulation, which are essential for haemostasis. Thus PAR-1 antagonism coupled with existing
dual oral antiplatelet therapy may potentially offer more comprehensive platelet inhibition without the liability of increased bleeding.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Platelets † Thrombosis † Antiplatelet therapy † Thrombin † PAR-1 antagonists
Introduction
Platelets play a key role in preventing blood loss after injury, but
they are also central in the formation of pathological thrombi
responsible for the acute clinical manifestations of atherothrombo-
tic disease. Platelet activation is crucial to haemostasis and the
development of pathological thrombosis and can be mediated by
multiple pathways. Key among these are the von Willebrand
factor, adenosine diphosphate (ADP), thromboxane A2 (TXA2),
and thrombin-mediated platelet activation pathways.
1 Current
oral antiplatelet agents inhibit the TXA2 (aspirin) and ADP
(P2Y12 ADP receptor antagonists) pathways, but not thrombin-
mediated platelet activation via protease-activated receptor-1
(PAR-1) binding. Thus despite receiving current standard-of-care
dual oral antiplatelet therapy (aspirin and clopidogrel), patients
continue to experience ischaemic events due to other platelet acti-
vation pathways. Furthermore, aspirin and P2Y12 ADP receptor
antagonists are associated with increased bleeding risk, as they
impair platelet pathways essential for primary haemostasis. Throm-
bin receptor antagonists (TRAs or PAR-1 antagonists) represent a
promising new class of oral antiplatelet agents for the treatment or
prevention of atherothrombotic disease. This article will summar-
ize the pathophysiology of atherothrombosis and the role of plate-
let activation pathways, the beneﬁts and limitations of current
standard-of-care therapy, thrombin–PAR-1 biology [including the
rationale for thrombin receptor (PAR-1) inhibition for improved
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in clinical development.
Platelet activation and
atherothrombosis
Platelets play a critical role in atherothrombosis, in that they
mediate thrombosis, the major pathogenic event in disease pro-
gression.
2 Excessive platelet activation subsequent to plaque
rupture or erosion overcomes regulatory haemostatic mechanisms
and leads to generation of unwarranted levels of thrombin,
initiating thrombosis and resulting in the formation of occlusive
thrombi at sites of plaque disruption.
2 Platelet activation can be
induced by the cooperative actions of multiple factors, including
serotonin, epinephrine, thrombin, ADP, and TXA2.
1,3 Key among
the soluble agonists are ADP and TXA2, which are released
from adherent, activated platelets, and thrombin, which is pro-
duced locally by tissue factor (Figure 1).
4 These agonists signal
through G protein-coupled receptors (GPCRs) expressed by
platelets and mediate paracrine and autocrine platelet activation.
3
Platelet activation by these factors leads to platelet shape
change,
5,6 expression of proinﬂammatory molecules [P-selectin,
7
soluble CD40 ligand (sCD40L)
8] and other unidentiﬁed proteins,
9
expression of platelet procoagulant activity,
10 potentiation of
aggregation by other prothrombotic factors such as collagen,
11
and, importantly, the conversion of the central platelet receptor
GPIIb/IIIa into an active form.
1 A protective haemostatic plug
develops into a vessel-occluding thrombus when exaggerated
platelet activation occurs under pathological conditions. Conse-
quently, agents targeting platelet activation pathways have
become the mainstay of antithrombotic therapy.
Figure 1 Sites of action of current and emerging antithrombotic drugs and antiplatelet agents. Adapted with permission. (Copyright & 2007
American Heart Association. All rights reserved.)
4 Platelet adherence to the endothelium occurs at sites of vascular injury through the binding
of GP receptors to exposed extracellular matrix proteins (collagen and vWF). Platelet activation occurs via complex intracellular signalling pro-
cesses and causes the production and release of multiple agonists, including TXA2 and ADP, and local production of thrombin. These factors
bind to their respective G protein-coupled receptors, mediating paracrine and autocrine platelet activation. Further, they potentiate each
other’s actions (P2Y12 signalling modulates thrombin generation). The major platelet integrin GPIIb/IIIa mediates the ﬁnal common step of plate-
let activation by undergoing a conformational shape change and binding ﬁbrinogen and vWF leading to platelet aggregation. The net result of
these interactions is thrombus formation mediated by platelet/platelet interactions with ﬁbrin. Current and emerging therapies inhibiting platelet
receptors, integrins, and proteins involved in platelet activation include the thromboxane inhibitors, the ADP receptor antagonists, the GPIIb/IIIa
inhibitors, and the novel PAR antagonists and adhesion antagonists. TP, thromboxane receptor; 5-HT2A, 5-hydroxy tryptamine 2A receptor.
Reversible-acting agents are indicated by brackets.
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antiplatelet therapy: beneﬁts
and limitations
Aspirin in combination with the thienopyridine clopidogrel is cur-
rently available as standard-of-care oral, dual antiplatelet therapy
for reducing ischaemic events in patients with atherothrombotic
disease. Aspirin is an irreversible cyclooxygenase-1 (COX-1)
inhibitor that inhibits platelet activation by blocking TXA2 pro-
duction,
12 whereas clopidogrel prevents platelet activation by irre-
versibly inhibiting the major platelet ADP receptor P2Y12
(Figure 1).
4,5,13 Clinical trials have conﬁrmed the therapeutic
beneﬁts of aspirin and clopidogrel in preventing thrombotic
events in a broad range of patients with atherothrombotic diseases.
The beneﬁts of aspirin have been shown in acute coronary
syndrome (ACS),
14,15 percutaneous coronary intervention
(PCI),
16 and primary
17 and secondary prevention of vascular
events or death.
14 The clinical efﬁcacy of clopidogrel has been
shown both as single antiplatelet therapy in high-risk patients
with various manifestations of atherosclerotic disease,
18 and in
conjunction with aspirin in high-risk patients with ACS, including
unstable angina, ST-segment elevation (STE) myocardial infarction
(MI), and non-STE (NSTE) MI, or those undergoing PCI.
19–22 The
third-generation thienopyridine prasugrel, with a faster onset of
action than clopidogrel, demonstrated superior efﬁcacy to clopido-
grel in the Trial to Assess Improvement in Therapeutic Outcomes
by Optimizing Platelet Inhibition With Prasugrel (TRITON-TIMI
38) in patients with ACS undergoing PCI.
23
Despite the beneﬁt associated with these agents, signiﬁcant
clinical limitations are associated with use of aspirin and a P2Y12
ADP receptor antagonist. The ﬁrst among these is the risk of
bleeding.
19,24 A dose-dependent increase in bleeding has been
shown with aspirin.
25 Although adjunctive therapy with clopidogrel
in addition to aspirin reduces the risk of ischaemic events, this
signiﬁcantly increases the risk of TIMI major and minor bleeding
and the need for transfusions.
19 The dose of aspirin used in
combination with clopidogrel contributes to the risk of bleeding
complications.
25 In TRITON, prasugrel, a more potent P2Y12
ADP receptor antagonist, was associated with a greater risk of
major bleeding vs. clopidogrel (2.4 vs. 1.8%, P ¼ 0.03), indicating
that the bleeding risk increases proportionally with the degree of
P2Y12 inhibition.
23 Bleeding risk has been attributed to the fact
that aspirin and P2Y12 ADP receptor antagonists interfere with
the TXA2 and ADP platelet activation pathways that are crucial
for normal haemostasis. Furthermore, P2Y12 signalling plays an
important role in the initiation of coagulation by modulating
thrombin generation (Figure 1).
26,27 More potent P2Y12 inhibition
by means of high loading and maintenance doses of clopidogrel
is associated with reduced ex vivo thrombus cohesion and
increased time to the ex vivo generation of the initial
platelet-ﬁbrin clot.
28–30 The active metabolite of prasugrel has
also been shown to reduce the kinetics of thrombin generation
induced by ADP and to inhibit clot strength.
31 This interplay
between P2Y12 signalling and thrombin generation
26,27 may
underlie the increased bleeding observed with the use of more
potent P2Y12 inhibitors.
Apart from bleeding risk, a considerable number of patients
receiving dual antiplatelet therapy continue to experience recur-
rent thrombotic events. This residual risk may be due to the
potential for continuing platelet activation and thrombosis via path-
ways independent of TXA2 and ADP. Multiple pathways contribute
to platelet activation, but aspirin and P2Y12 ADP receptor antagon-
ists do not inhibit pathways other than those stimulated by TXA2
and ADP, respectively.
1 This potentially contributes to the
increased incidence of thrombotic events in patients due to
ongoing platelet activation via potent agonists such as thrombin,
thereby increasing patient morbidity and mortality. New therapies
that target pathways that are not affected by aspirin or P2Y12 ADP
receptor antagonists could provide complementary and more
comprehensive inhibition of platelet activation when used in com-
bination with the current standard-of-care therapies, and thereby
contribute to greater inhibition of platelet-mediated thrombosis.
Finally, inadequate responsiveness to aspirin and clopidogrel has
been shown in several studies to be associated with poor clinical
outcomes (a full description of aspirin and clopidogrel resistance
goes beyond the scope of this review and is described else-
where).
13,32,33 The variability in response is characterized by the
inability of these agents to completely inhibit the COX-1 enzyme
and TXA2 generation (by aspirin) and the ADP P2Y12 receptor
(by clopidogrel), via mechanisms that are multifactorial and not
fully elucidated. To date, phosphodiesterase inhibitors, such as
cilostazol, have only partly been able to overcome this limitation.
34
Thus the challenge at present is to develop antiplatelet agents
that inhibit thrombosis but leave haemostasis sufﬁciently intact
to prevent bleeding. It is hoped that novel P2Y12 receptor
antagonists—prasugrel and ticagrelor—as well as antiplatelet
therapies currently in clinical testing targeting novel pathways,
such as the TRAs SCH 530348 and E-5555, will have superior
clinical proﬁles to those of currently approved antiplatelet
agents.
35–37
Thrombin–protease-activated
receptor-1 biology and rationale
for thrombin receptor
(protease-activated receptor-1)
inhibition
The serine protease thrombin is considered to be one of the most
potent platelet activators and plays a seminal role in blood coagu-
lation.
38 The potency of thrombin is supported by studies showing
that among the pro-thrombotic activities of thrombin, platelet acti-
vation is observed most rapidly and requires the lowest biologically
active thrombin concentration (0.5 nM).
39 In contrast, ex vivo
studies of platelet aggregation require micromolar concentrations
of other platelet activators such as ADP.
40 Furthermore, thrombin
is a more potent agonist than either thrombin receptor activating
peptide (TRAP) or other activating peptides.
41 Platelet responses
to thrombin are mediated by surface GPCRs known as PARs or
thrombin receptors. In humans, there are four known subtypes
of PARs, which display wide tissue distribution (Table 1).
42,43
PAR-1, PAR-3, and PAR-4 are activated by thrombin, whereas
Platelet thrombin receptor antagonism 19PAR-2 is activated by trypsin and trypsin-like proteases and not by
thrombin.
38 Thrombin-mediated platelet activation in humans is
shown to occur through PAR-1 and PAR-4 receptors.
38 PAR-1
acts as the principal thrombin receptor on human platelets and
mediates platelet activation by subnanomolar thrombin concen-
trations, whereas PAR-4 requires higher concentration of throm-
bin for activation (Table 1).
38,43,44 Thrombin is also known to
cleave PAR-3; however, the physiological relevance of this inter-
action is not known.
45 PAR-3 can dimerize with other PARs,
which may contribute to regulation of PAR signalling.
45
A unique tethered ligand mechanism has been described for
thrombin-mediated platelet activation via PAR.
38,46 Thrombin’s
ﬁbrinogen-binding exosite binds the hirudin-like extracellular
amino (NH2) terminal domain of PAR-1 on the platelet surface,
cleaves the receptor between arginine 41 and serine 42,
removes the amino terminal sequence, and generates a new
protonated amino group at the NH2 terminal of the tethered
ligand—S
42FLLRN (serine–phenylalanine–leucine–leucine–argi-
nine–asparagine). This newly exposed NH2 terminus sequence
acts as the tethered ligand and binds intramolecularly to the
body of the receptor, activating it.
46 The hirudin-like sequence is
important for receptor cleavage at low concentrations of thrombin
and is present in PAR-1 and PAR-3.
47 PAR-4 lacks the hirudin-like
sequence and thereby requires far greater levels of thrombin for
activation.
44,47 PAR-4 uses instead a negatively charged cluster of
amino acid residues to facilitate slow disassociation from the posi-
tively charged thrombin molecule.
48 PAR-2 also lacks the hirudin-
like sequence and cannot be cleaved by thrombin.
38,47,49 Thrombin
also binds to GPIba on the surface of human platelets, which has
been proposed to act as a cofactor that localizes thrombin to the
platelet surface to support thrombin cleavage of PARs.
38,50
Thrombin-mediated PAR-1 cleavage results in the activation of
heterotrimeric G proteins of the Ga12/13, Gaq, and Gai/z families
that interconnect several intracellular signalling pathways to the
various phenotypic effects of thrombin on platelets (Figure 2).
6,38
These include TXA2 production,
51 ADP release,
52 serotonin and
epinephrine (adrenaline) release,
53,54 activation/mobilization of
P-selectin and CD40 ligand,
55,56 integrin activation,
57 and platelet
aggregation.
58 PAR-1 activation also stimulates platelet
procoagulant activity, leading to enhanced thrombin formation,
10
and the generation of ﬁbrin from ﬁbrinogen.
59 PAR-4, like
PAR-1, mediates its effects by activating Gaq and Ga12/13 signal-
ling
6; however, unlike PAR-1, PAR-4 may not activate or require
Gai signals.
52,60 PAR-4 is activated, shut off, and internalized
more slowly than PAR-1 and produces the majority of the inte-
grated thrombin-triggered calcium signals of the two recep-
tors.
52,61 PAR-4 can also be activated by cathepsin G, a
granzyme (serine esterase) released by neutrophils
62; however,
the relevance of this function in vivo is not known. A counter-
regulatory mechanism of PAR-1 and PAR-4 activity has been
described in the control of platelet function, whereby PAR-1 acti-
vation causes release of vascular endothelial growth factor and
PAR-4 activation causes release of endostatin.
63 The importance
of these qualitative differences between PAR-1 and PAR-4 signal-
ling for platelet function is not fully understood. The current
hypothesis is that PAR-4 functions as an auxiliary receptor mediat-
ing thrombin signalling to distinct effectors or with different kin-
etics compared with PAR-1. PAR-4 may perhaps also interact
directly or indirectly with PAR-1 or mediate platelet responses
to proteinases other than thrombin.
6,61 Indeﬁnite signalling from
PAR receptors is prevented by efﬁcient receptor desensitization
(via phosphorylation for PAR-1 but not for PAR-4
61), receptor
endocytosis, and delivery to lysosomes for degradation.
38,64
The P2Y12 and PAR-1 pathways are known to cross-react in
mediating platelet activation.
65,66 Potent platelet activation has
been shown to require coactivation of Gaq- and Gai-coupled
receptors.
67,68 Unlike ADP, which directly activates both Gai
(via P2Y12) and Gaq (via P2Y1) signalling,
67 thrombin cannot
directly activate both signals and requires the secondary Gai
signal from P2Y12 and secreted ADP (thrombin’s secondary
response) to complement the Gaq signals from PAR-1 and
PAR-4.
65,66 Gai signalling inhibits adenylyl cyclase, thereby
decreasing the concentration of cyclic adenosine monophosphate,
which is an inhibitor of platelet activation (Figure 2).
38,66,69
Thrombin-dependent platelet aggregation is known to be mediated
at least in part by secreted ADP acting on the Gai-linked ADP
receptor in murine and human platelets.
66,70–72 Building on
these observations, the combined inhibition of thrombin and
.............................................................................................................................................................................
Table 1 Properties of human protease-activated receptor family members and phenotype of mice lacking each
receptor
Primary activating
protease
43
Localization
42 Phenotype of knockout mice
43
PAR-1 Thrombin (50 pmol/L) Platelets, endothelium, epithelium,
ﬁbroblasts, myocytes, neurons,
astrocytes
Partial embryonic lethality, vascular matrix deposition after injury
PAR-2 Trypsin (1 nmol/L);
Tryptase (1 nmol/L)
Endothelium, epithelium, ﬁbroblasts,
myocytes, neurons, astrocytes
Impaired leucocyte migration; impaired allergic inﬂammation of
airway, joints, kidney
PAR-3 Thrombin (0.2 nmol/L) Endothelium, myocytes, astrocytes Delayed response to thrombin; no spontaneous bleeding; normal
platelet counts; protection against thrombus formation/pulmonary
embolism
PAR-4 Thrombin (5 nmol/L);
Trypsin (1 nmol/L)
Platelets, endothelium, myocytes,
astrocytes
Unresponsive to thrombin; no spontaneous bleeding; normal platelet
counts; protection against thrombus formation/pulmonary
embolism
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tory effect on thrombin-induced platelet activation and aggrega-
tion, via a mechanism that was proposed to involve concurrent
inhibition of Gaq (via PAR-1) and Gai (via P2Y12) signals required
for potent platelet activation.
73 P2Y12 blockade was shown to be
most effective at low (physiological) thrombin concentrations
that are sufﬁcient to cleave PAR-1 and release all of the ADP
while leaving PAR-4 intact.
52,69 Importantly, the synergistic inhi-
bition was achieved with much lower dose combinations of throm-
bin and P2Y12 inhibitors than single doses of the inhibitors required
for the same effect.
73
In the vessel wall, PARs also mediate responses involved in con-
tractility, proliferation, inﬂammation, and repair. Endothelial cells
express all four PAR family members.
45 Preclinical studies have
shown that activation of PAR-1 or PAR-2 induces vascular relax-
ation mediated by the production of nitric oxide.
45 PAR-1 agonists
have also been shown to have the opposite effect on vascular tone,
inducing contraction of vascular smooth muscle cells.
74 Prolifer-
ation of cultured vascular smooth muscle cells has also been
observed in response to PAR-1, PAR-2, and PAR-4 activation.
PAR-2 also has proliferatory and angiogenic effects on endothelial
cells. Other studies have suggested that PARs can promote inﬂam-
mation by enhancing leucocyte adherence to endothelial cells and
migration of leucocytes from the vasculature into inﬂamed tissue.
45
In atherogenic human arteries, expression of PAR-1 is enhanced in
inﬂamed endothelium displaying macrophage inﬂux and smooth
muscle cell proliferation.
6 PAR-2 and PAR-4 have also been impli-
cated in inﬂammatory responses.
45 In contrast to the species differ-
ence in PAR expression on mouse vs. human platelets, PAR-1 is
the major PAR family member present in endothelial cells in
both mice and humans.
38 PAR-1 deﬁciency or blockade in mice
reduces leucocyte inﬁltration and inﬂammation. PAR-1 antagonism
has been shown to be protective in animal models of vascular
injury.
75
Murine platelets utilize PAR-4 and PAR-3 receptors to respond
to thrombin. PAR-4 is the principal thrombin receptor in mice.
38
PAR4
2/2 mice are unresponsive to thrombin, display no spon-
taneous bleeding, and are protected from thrombosis
(Table 1).
62 Activation of PAR-3, a high afﬁnity thrombin receptor,
alone does not result in thrombin signalling. PAR3
2/2 mice exhibit
Figure 2 Intracellular signalling pathways and phenotypic effects mediated by PAR-1 activation by thrombin in platelets. Reproduced with
permission. (Copyright & 2005 International Society on Thrombosis and Haemostasis. All rights reserved.)
38 Members of the Ga12/13,
Gaq, and Gai/z families activate PAR-1 signalling pathways. First, the a-subunits of G12 and 13 bind RhoGEFs (which activate small G proteins)
and drive Rho-mediated cytoskeletal responses leading to changes in platelet morphology. Second, Gaq activates phospholipase Cb and trig-
gers phosphoinositide hydrolysis, calcium mobilization, and protein kinase C activation. This then activates pathways leading to granule
secretion, as PAR-1–Gaq-coupled ADP release is especially important for thrombin-mediated platelet activation. In addition, calcium-regulated
kinases and phosphatases, GEFs, MAP kinases, and other proteins that mediate platelet aggregation are activated. Gai promotes platelet
responses by inhibiting adenylyl cyclase. Gbg subunits can activate phosphoinositide-3 kinase, other lipid-modifying enzymes, protein
kinases, MAP kinase cascades, and channels. Phosphoinositide-3 kinase modiﬁes the inner leaﬂet of the plasma membrane to provide molecular
docking sites. Finally, PAR-1 also promotes growth factor shedding and activation of receptor tyrosine kinases involved in cell growth and differ-
entiation. GEF, guanine nucleotide exchange factors; MAP, mitogen-activated protein; IP3, inositol triphosphate 3; DAG, diacylglycerol; WASP,
Wiskott–Aldrich syndrome protein; SRE, serum response element; MLC, myosin light chain.
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76,77 PAR-3 in murine platelets is
proposed to serve as a cofactor, concentrating thrombin at the
cell surface and promoting cleavage and activation of PAR-4 at
low thrombin concentrations. Thus, in contrast to the human
system, platelet activation in mice requires cooperative interaction
between PAR-3 and PAR-4. The phenotypes of PAR knockout
mice are indicated in Table 1.
Rationale for thrombin receptor
(protease-activated receptor-1)
inhibition for treatment of
atherothrombotic disease
In contrast to the ADP and the TXA2 platelet activation pathways
that are crucial for both routine haemostasis and pathological
thrombosis, PAR-1-mediated platelet activation contributes to
pathological thrombosis (formation of occlusive platelet-rich
thrombus) but may not be required for protective haemostasis
(formation of the initial platelet monolayer). Observations from
several pre-clinical studies indicate that thrombin-mediated clea-
vage of ﬁbrinogen into ﬁbrin is more important for haemostasis
than thrombin-mediated platelet activation.
38 In contrast to the
severe bleeding phenotype exhibited by mice deﬁcient in ﬁbrino-
gen, PAR-4-deﬁcient mice (Par-4
2/2) exhibit normal platelet
numbers and morphology, appear healthy, and do not show
undue anaemia or spontaneous bleeding.
62,78,79 Par-4
2/2 mice
have reduced and delayed platelet activation (measured by P-
selectin expression) and diminished growth of thrombi, with no
difference in kinetics or quantity of ﬁbrin accumulation compared
with wild-type mice.
80 Initial platelet accumulation at sites of injury
was not different between wild-type and Par-4
2/2 mice, and this
early thrombus was proposed to support thrombin generation in
sufﬁcient amounts and allow normal ﬁbrin deposition observed
in this model.
80 Although a direct association between murine
and human PAR function in platelets cannot be made because of
species-dependent differences in expression, these ﬁndings
suggest that platelet activation by thrombin is distinct and less
important for haemostasis than ﬁbrin generation. In addition,
PAR-1 inhibition using the PAR-1 antagonist FR171113 has been
shown to reduce arterial thrombosis in guinea pigs by reducing
Figure 3 Role of thrombin-mediated PAR-1 signalling in haemostasis vs. thrombosis: rationale for PAR-1 antagonist.
38 In addition to activating
PARs on platelets, thrombin facilitates ﬁbrin formation and protein C activation. Available data in mice and non-human primate models indicate
that PAR antagonists have the potential to block platelet activation by thrombin while sparing these other functions of thrombin, including
coagulation, that are absolutely necessary for haemostasis. Murine studies suggest that ﬁbrin(ogen) is relatively more important than
thrombin-induced platelet activation for haemostasis, and this is supported by high bleeding risk associated with the use of anticoagulants in
man. Thus, inhibition of thrombin-induced platelet activation might provide for a larger therapeutic index than can be achieved with coagulation
inhibitors for the prevention or treatment of thrombosis.
D.J. Angiolillo et al. 22PAR-1 agonist- or thrombin-induced platelet aggregation without
prolonging bleeding times or inﬂuencing coagulation parameters.
81
In contrast, the direct thrombin inhibitor argatroban inhibited
thrombus formation but signiﬁcantly prolonged bleeding and
coagulation times in this study. Although extrapolation of these
results to humans is highly speculative, these ﬁndings are suggestive
of differentiation among antithrombotic agents based on the
beneﬁt/risk (i.e. bleeding) ratio. PAR-1 inhibition with FR171113
did not inhibit ADP-induced or collagen-induced platelet aggrega-
tion, suggesting that PAR-1 antagonism does not affect platelet
activation pathways required for protective haemostasis. Inhibition
of ADP signalling with AR-C69931MX (cangrelor) and, to a lesser
extent, inhibition of TXA2 signalling with indomethacin have been
shown to inhibit platelet adhesion to immobilized collagen,
demonstrating that inhibition of these pathways disrupts normal
haemostasis.
82 Of note, guinea pig platelets differ from human
platelets in that they express PAR-1, -2, and -3.
42 However,
FR171113 has similar antithrombotic effects in human platelets,
suggesting a similar role for PAR-1 signalling between humans
and guinea pigs.
81,83 As in human platelets, platelets from non-
human primates express PAR-1 and PAR-4.
84 Treatment with a
PAR-1 antagonist (RWJ-58259) or antibodies to PAR-1 in non-
human primate models reduced vascular injury-induced thrombo-
sis while sparing platelet-dependent coagulation functions such as
the activated clotting time, activated partial thromboplastin time,
and prothrombin times. Haematological parameters such as red
blood cell count, haematocrit, white blood cell count, or platelet
counts were not affected by PAR-1 inhibition.
84,85 Importantly,
thrombin signalling through the PAR-4 receptor remained intact
in these studies, indicating a primary role for PAR-1 in mediating
thrombin’s prothrombotic effects in non-human primates. This
suggests that inhibition of PAR-1 alone may be similarly sufﬁcient
in the prevention or treatment of thrombotic events in humans.
These pre-clinical ﬁndings are also consistent with clinical
observations showing substantial bleeding risk in patients treated
with anticoagulants that interfere with the catalytic function of
thrombin.
86 Inhibition of PAR-1 function rather than inhibition of
thrombin generation or activity (e.g. by factor Xa inhibitors) there-
fore provides a rational strategy for treatment of thrombotic dis-
orders in humans. Platelets retain responsiveness to thrombin
(albeit at much higher doses) via intact PAR-4 signals utilizing
ADP/P2Y12/Gai-independent mechanisms.
52,60,66 Indeed, defective
Gai signalling is known to be associated with chronic bleeding dis-
order in humans and is characterized by impaired platelet aggrega-
tion responses to ADP and epinephrine.
71,87 These erroneous
signalling events may underlie the increased bleeding observed
with use of the more potent irreversible P2Y12 inhibitor prasugrel
when compared with clopidogrel.
23
Thrombin receptor antagonists
in clinical development
Two TRAs are currently in clinical trials for the treatment and pre-
vention of arterial thrombosis, SCH 530348 and E-5555
(Figure 4).
88,89
SCH 530348 (thrombin receptor
antagonist)
SCH 530348 is a high-afﬁnity, orally active, low-molecular weight,
non-peptide, competitive PAR-1 TRA.
88 Pre-clinical functional
assays have shown potent inhibition of thrombin and
TRAP-induced platelet aggregation by SCH 530348.
88 In addition,
SCH 530348 was inactive in functional assays with PAR-2,
PAR-3, and PAR-4 and did not affect clotting parameters such as
prothrombin time. A study in cynomolgus monkeys revealed no
bleeding risk with the administration of SCH 530348 (1 mg/kg)
alone, and no increase in bleeding time when used in combination
with aspirin plus clopidogrel.
90 These results suggest that SCH
530348 is a potent and selective PAR-1 antagonist that does not
impact bleeding and supported further clinical evaluation.
Dose-ranging studies (daily doses of 0.5, 1.0, or 2.5 mg for 28
days or single doses of 5.0, 10, 20, or 40 mg) in healthy volunteers
Figure 4 PAR-1 antagonists in clinical development. Reproduced with permission. (Copyright & 2006 and 2008. The American Chemical
Society. All rights reserved.)
88,89 Chemical structure of PAR-1 antagonist SCH 530348 and presumed structure of E-5555.
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of platelet aggregation induced by 15 mM TRAP.
91 SCH 530348
was rapidly absorbed and slowly eliminated, with a mean terminal-
phase half-life (t1/2) of 165–311 h. Recovery of platelet function to
 50% of baseline was dose-dependent and occurred at 4 weeks
after treatment discontinuation.
92 SCH 530348 was safe and well
tolerated after single oral doses up to 40 mg and multiple doses
up to 5 mg daily in healthy volunteers.
93 There were no signiﬁcant
changes in the results of laboratory tests, including tests of liver
and kidney function, coagulation parameters, and vital signs or
ECGs including speciﬁc changes in the QT interval, or any signiﬁ-
cant effect on Ivy bleeding times with SCH 530348 vs. placebo
groups.
The Phase 2 Thrombin Receptor Antagonist-Percutaneous Cor-
onary Intervention (TRA-PCI) trial evaluated the safety and efﬁcacy
of SCH 530348 used in combination with standard oral antiplatelet
therapy (aspirin and clopidogrel) and an antithrombin agent
(heparin or bivalirudin) over a 60-day treatment duration in a
total of 1030 patients undergoing non-urgent PCI or coronary
angiography with planned PCI. Patients were randomized to
receive one of three oral loading doses of SCH 530348 (10, 20,
or 40 mg) or placebo in addition to aspirin plus clopidogrel.
Patients who underwent PCI (n ¼ 573) were randomized to
receive one of three oral daily maintenance doses of SCH
530348 (0.5, 1, or 2.5 mg) or placebo.
94 There was no signiﬁcant
difference in the primary endpoint of rate of TIMI major bleeding
(e.g. any intracranial haemorrhage or overt sign of bleeding requir-
ing intervention and associated with a decrease in haemoglobin
concentration of .5 g/dL) and minor bleeding (e.g. any overt
sign of bleeding requiring intervention that did not meet the
requirements for TIMI major bleeding and associated with a
decrease in haemoglobin concentration of 3 to  5 g/dL)
between patients who underwent PCI at the end of the 60-day
treatment (3% in the collective SCH 530348 treatment arms vs.
3% with standard care therapy). TIMI major plus minor bleeding
was observed in 2, 3, and 4% of patients receiving SCH 530348
10, 20, and 40 mg loading dose, respectively. Non-coronary
artery bypass graft TIMI major plus minor bleeding was observed
in less than 1, 3, and 4% of patients receiving 10, 20, and 40 mg,
respectively (vs. 3% with placebo). No signiﬁcant trends were
observed. TIMI major plus minor bleeding was observed in 2, 4,
and 3% of patients receiving SCH 530348 0.5, 1.0, and 2.5 mg/d
maintenance dose, respectively. The combination of SCH 530348
40 mg oral loading dose plus a 2.5 mg/d maintenance dose (the
highest dose combination tested) was associated with no cases
of TIMI major bleeding vs. no cases with placebo and two cases
(3%) of TIMI minor bleeding vs. one case (2%) with placebo.
The incidence of death, major adverse cardiovascular events
(MACE), or stroke was not signiﬁcantly different between the
SCH 530348 and placebo groups (6% in the collective SCH
530348 groups vs. 9% with placebo). There was a non-signiﬁcant
trend for dose-dependent reduction in the secondary outcome
of non-fatal MI in the SCH 530348 groups vs. the placebo group
(5, 4, and 3% with SCH 530348 10, 20, and 40 mg loading dose
vs. 7% with placebo).
94 SCH 530348 also demonstrated dose-
dependent inhibition of TRAP-induced platelet aggregation.
94
The 40 mg loading dose was the most effective; it inhibited
TRAP-induced platelet aggregation in almost 30% of patients as
early as 0.5 h after administration and by 2 h this proportion had
more than tripled. Levels of inhibition were sustained at 30 and
60 days with 1.0 and 2.5 mg maintenance doses. Furthermore, a
substudy of TRA-PCI evaluated the effect of SCH 530348 on plate-
let aggregation induced by various agonists. SCH 530348 did not
have any measurable effects on platelet aggregation induced by
ADP, arachidonic acid, or collagen, supporting the speciﬁcity of
SCH 530348 for PAR-1.
95
The safety and tolerability of SCH 530348 was also conﬁrmed in
a recent Phase 2 clinical trial in Japanese patients with NSTE ACS
(n ¼ 117).
96 Addition of SCH 530348 (either 20 or 40 mg loading
dose, followed by 1 or 2.5 mg maintenance dose) for 60 days to
standard of care (aspirin, ticlopidine, and heparin) was not associ-
ated with an increase in the occurrence of the key safety endpoint
of TIMI major and minor bleeding or non-TIMI bleeding vs. patients
receiving standard of care plus placebo, conﬁrming the previous
ﬁndings in elective PCI. Patients undergoing PCI (primary
cohort) treated with SCH 530348 plus standard of care (n ¼ 71)
experienced a signiﬁcant reduction in periprocedural MI (deﬁned
as a more than 3-fold elevation in creatine kinase-myocardial
band or troponin I, with  50% increase from baseline) compared
with the 21 patients receiving standard of care alone (16.9 vs.
42.9%, respectively; 61% relative reduction, P ¼ 0.013). There
were no deaths or any other MACE.
96 The data from these
Phase 2 trials demonstrate the potential clinical beneﬁt of SCH
530348 when incorporated into the standard-of-care therapy for
patients with vascular atherothrombotic disease undergoing PCI.
Taken together, the results of these initial studies indicate that
SCH 530348 has the potential to reduce recurrent ischaemic
events without exposing patients to increased bleeding risk.
These ﬁndings provide a rationale for evaluation of SCH 530348
used in combination with current standard-of-care dual antiplatelet
therapy in Phase 3 trials. Two Phase 3 trials for SCH 530348 are
currently ongoing. The Thrombin Receptor Antagonist in Second-
ary Prevention of Atherothrombotic Ischaemic Events
(TRA-2P-TIMI 50, NCT00526474) is a multinational, double-blind,
randomized, placebo-controlled trial that is evaluating the efﬁcacy
of SCH 530348 plus standard of care, which includes aspirin and/or
clopidogrel therapy, in the secondary prevention of ischaemic
events in patients with prior MI, stroke, or PAD and is recruiting
20 000 patients. Patients are randomized to receive a 2.5 mg
maintenance dose of SCH 530348 or placebo as secondary pre-
vention. The primary endpoint of the trial is the composite of car-
diovascular death, MI, urgent coronary revascularization, or stroke.
The key secondary endpoint is cardiovascular death, MI, or stroke.
Patients are being followed for a minimum of 1 year. The Phase 3
Thrombin Receptor Antagonist Clinical Event Reduction in Acute
Coronary Syndrome (TRA-CER, NCT00527943) trial is a multina-
tional, randomized, double-blind, placebo-controlled study evaluat-
ing the primary prevention of ischaemic events in 10 000 patients
with NSTE ACS over  1 year of follow-up with a loading dose of
SCH 530348 40 mg and a maintenance dose of SCH 530348
2.5 mg in addition to aspirin and clopidogrel. The primary endpoint
is the composite of cardiovascular death, MI, stroke, rehospitaliza-
tion for ACS, and urgent revascularization; the secondary endpoint
is the composite of cardiovascular death, MI, and stroke.
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E-5555 is a novel, orally active, potent PAR-1 antagonist that has
demonstrated antiplatelet effects without increasing bleeding
times in pre-clinical studies (Figure 4).
89 Upon incubation with
human platelet-rich plasma from healthy volunteers, E-5555 was
shown to inhibit thrombin- and TRAP-mediated sCD40L release
(IC50: 47 and 38 nM, respectively) without affecting ADP-induced
sCD40L release.
97 E-5555 also inhibited thrombin-induced release
of interleukin-6 and P-selectin expression in human coronary
artery smooth muscle cells and human coronary artery endothelial
cells.
97 Interestingly, E-5555 was also shown to prevent vascular
spasm at the site of intracranial bleeding in rabbits.
98 The in vitro
effects of E-5555 on platelet function in blood samples from
healthy subjects (n ¼ 10), patients with coronary artery disease
(CAD) treated with aspirin (n ¼ 10), and patients with CAD
treated with aspirin plus clopidogrel (n ¼ 10) were recently
reported.
99 Thrombin receptor activating peptide-induced platelet
aggregation was inhibited almost completely at all tested doses of
E-5555 (20 and 50 ng/mL and 100 mg/mL).
99 No dose-dependent
effect was observed at the doses used in the study. The safety and
tolerability of a once-daily oral dose of E-5555 50, 100, or 200 mg
and its effects on inhibition of platelet aggregation, endovascular
inﬂammatory processes, and the incidence of MACE is being eval-
uated over 24 weeks in patients with CAD aged 45–80 years and
over 12 weeks in patients with NSTE ACS aged 45–80 years in
two randomized, double-blind, placebo-controlled Phase 2 clinical
trials called Lessons From Antagonizing the Cellular Effects of
Thrombin (LANCELOT) 201 and 202 (NCT00312052 and
NCT00548587). The enrolment for each study is anticipated to
be about 600 patients.
Conclusion
Platelet activation is crucial for normal haemostasis but may also
lead to the formation of occlusive platelet-rich thrombi, respon-
sible for the manifestations of atherothrombotic disease. Conse-
quently, antiplatelet agents such as aspirin and clopidogrel have
become the cornerstone of treatment for patients with athero-
thrombotic complications. Although aspirin alone or in combi-
nation with clopidogrel has demonstrated signiﬁcant clinical
beneﬁts, the residual morbidity and mortality associated with
ischaemic events remains substantial in patients receiving such
therapy, and these agents are associated with bleeding compli-
cations, emphasizing the need for antiplatelet therapies that
afford more comprehensive platelet inhibition without increasing
bleeding risk. The PAR-1-mediated platelet activation pathway via
thrombin is a key contributor to platelet-mediated thrombosis,
but it does not play a critical role in haemostasis. Thus PAR-1
antagonists may provide more comprehensive antithrombotic
effects when used in combination with the current standard of
care, with the potential to incrementally reduce atherothrombotic
complications without increased bleeding risk. Results from Phase
2 trials of the PAR-1 antagonist SCH 530348 have provided prom-
ising data in support of this approach, in particular for patients
undergoing PCI. The PAR-1 antagonist E-5555 is currently under
Phase 2 clinical investigation and will provide further insights on
the safety and tolerability of PAR-1 blockade, as well as the poten-
tial to reduce ischaemic events when used in conjunction with
standard antiplatelet treatment regimens. Ongoing Phase 3 clinical
trials with SCH 530348 being performed in a very large cohort of
patients with various manifestations of atherosclerotic disease will
better deﬁne the overall net clinical beneﬁt associated with inhi-
bition of this important signalling pathway.
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